New directions in type 2 diabetes mellitus: An update of current oral antidiabetic therapy

Journal of the National Medical Association

Volumn 91, Issue 7, 1999, Pages 389-395

  Brown, Darwin L ^a,b   Brillon, David ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Diabet and Endocrinology Associates   (United States)

Author keywords

Diabetes mellitus; Hypoglycemic agents

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CARBAMIC ACID DERIVATIVE; CHROMAN DERIVATIVE; METFORMIN; PIPERIDINE DERIVATIVE; REPAGLINIDE; SULFONYLUREA DERIVATIVE; THIAZOLE DERIVATIVE; TROGLITAZONE;

HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

CARBAMATES; CHROMANS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PIPERIDINES; SULFONYLUREA COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0033155223     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bailey BJ, Lherisson-Cedeno D. Diabetes outcomes and practices: comparison of African Americans and caucasians. Journal of National Black Nurses Association. Spring/Summer 1997;9:66-75.
2. Smith-Veal Y. African Americans and diabetes: reasons, rationale, and research. J Natl Med Assoc. 1996;88:203-204.
3. Agrawal L, Emanuele NV, Abraira C, et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VACSDM). Diabetes Care. 1998;21:510-515.
4. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977-1036.
7. University Group Diabetes Program: a study of the effects of hypoglycemia agents on vascular complication in patients with adult onset diabetes. Diabetes. 1970;19(suppl 2):789-830.
8. Sonnenberg G, Garg DC, Weidler DJ, et al. Short-term comparison of once-versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother. 1997;31:671-676.
9. Clark HE, Matthews DR. The effect of glimepiride on pancreatic beta-cell function under hyperglycemic clamp and hyperinsulinemic, euglycemic clamp conditions in non-insulin dependent diabetes mellitus. Horm Metab Res. 1996;28:445-450.
10. Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs. 1998;55:563-584.
11. Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res. 1996;28:426-429.
12. Campbell RK, White JR, Saulie BA. Metformin: a new oral biguanide. Clin Ther. 1996;18:360-371.
13. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997;102:99-110.
14. Hollander P. New approaches to the treatment of type 2 diabetes. Resident and Staff Physician. 1998;44(8):21-29.
15. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6 year, randomized controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128:165-175.
16. Chiasson J, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med. 1994;121:928-935.
17. Buse J, Edelman S, Neumann C. The PROTECT Study Group: Precose, Resolution of Optimal Titration to Enhance Current Therapies (PROTECT) Study. Experience in patients with type II diabetes. Diabetes. 1997;46(suppl1):99A-100A.
18. Loh KC, Tan MH. Alpha-glucosidase inhibitors for treatment of diabetes. Endocrine Practice. 1998;4:287-293.
19. Riddle M. Learning to use troglitazone. Diabetes Care. 1998;21:1389-1390.
20. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes. N Engl J Med. 1998;338:867-872.
21. Gitlin N, Julie N, Spurr C, Lim K, Juarbe H. Two cases of severe clinical and histological hepatotoxicity associated with troglitazone. Ann Intern Med. 1998;129:36-38.
22. Neuschwander-Tetri BA, Isley WL, Oki JC, et al. Troglita-zone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med. 1998;129:38-41.
23. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes. 1998;47:345-351.
24. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317:708-713.
25. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
26. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1998;21(suppl):S5-S17.